Background Corticosteroids are commonly used to improve the rate of recovery from acute
exacerbation in multiple sclerosis (MS) patients. However, it is unclear just how effective …

The ability of glucocorticoids to interfere with post-transcriptional gene regulation has
recently been recognized as a potentially important part of their anti-inflammatory property …

Relapses, exacerbations or attacks of multiple sclerosis are the dominating feature of
relapsing‐remitting multiple sclerosis (MS), but are also observed in patients with secondary …

Glucocorticoids have three distinct therapeutically relevant effects (genomic, specific non-
genomic, and unspecific non-genomic), raising the hypothesis that the relative potencies of …

Multiple sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the central
nervous system characterized in the majority of the patients by a relapsing-remitting disease …

Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a
multiphasic course of neurological exacerbations, periods of clinical remission, and, in most …

Background–Multiple sclerosis (MS) is an immune‐mediated inflammatory disease of the
central nervous system (CNS) that usually is clinically characterized by repeated subacute …

A non‐genomic antisecretory role for dexamethasone at low concentrations (0.1 nm to1 μm)
is described in monolayers of human bronchial epithelial cells in primary culture and in a …

Impairment of cognitive skills is found in up to 65% of patients suffering from multiple
sclerosis (MS). Little is known concerning the natural history or characteristics of progression …

Cognitive impairment in multiple sclerosis (MS) has received considerable interest over the
last decades. Heterogeneous patterns of cognitive dysfunction have been reported in …